AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11406740 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral enteric‐coated pamidronate (300 mg daily)
Number of subjects: 12
Study 11406740 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (3 g daily)
Number of subjects: 12
Study 11406740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11406740 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pamidronate
Number of subjects: 12
Study 9230826 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2a (6.0 MIU)
Number of subjects: 481
Study 9230826 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2a (1.5 MIU)
Number of subjects: 481
Study 9230826 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2a (3.0 MIU)
Number of subjects: 481
Study 9230826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 481
Study 8214412 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 54
Study 8214412 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.05 BAC)
Number of subjects: 54
Study 8214412 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.08 BAC)
Number of subjects: 54
Study 8214412 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (without sleep deprivation)
Number of subjects: 54
Study 3624560 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% butyl methoxydibenzoylmethane and 7% padimate O
Number of subjects: 0
Study 3624560 — intervention group
Group type: COMPARATOR
Intervention: 7% padimate O
Number of subjects: 0
Study 3624560 — intervention group
Group type: COMPARATOR
Intervention: 5% octyl salicylate and 3% oxybenzone
Number of subjects: 0
Study 3624560 — intervention group
Group type: COMPARATOR
Intervention: 3% butyl methoxydibenzoylmethane alone
Number of subjects: 0
Study 3624560 — intervention group
Group type: COMPARATOR
Intervention: 7% padimate O alone
Number of subjects: 0
Study 3624560 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study 31724352 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-knife treatment, applied 1 time a week for 8 times, targeting specific anatomical points.
Number of subjects: 60
Study 31724352 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine sulfate, 0.2 g each time, 2 times daily for 4 weeks, total of 2 courses.
Number of subjects: 60
Study 27521445 — intervention group
Group type: EXPERIMENTAL
Intervention: subunit cancer vaccine (recMAGE‐A3 protein+AS15)
Number of subjects: 24
Study 27521445 — intervention group
Group type: EXPERIMENTAL
Intervention: subunit cancer vaccine (recMAGE‐A3 protein+AS15) with intravesical BCG
Number of subjects: 24
Study 27521445 — intervention group
Group type: COMPARATOR
Intervention: intravesical BCG
Number of subjects: 24
Study 26039969 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant 20 mg
Number of subjects: 28
Study 26039969 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant 40 mg
Number of subjects: 28
Study 26039969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 26039969 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 28
Study 23729804 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) withdrawal
Number of subjects: 45
Study 23729804 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment using other agents
Number of subjects: 45
Study 20811901 — intervention group
Group type: EXPERIMENTAL
Intervention: DISE-TCI
Number of subjects: 40
Study 20811901 — intervention group
Group type: COMPARATOR
Intervention: Conventional DISE
Number of subjects: 40
Study 18989589 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate autologous bone graft combined with secondary dental implant
Number of subjects: 16
Study 18989589 — intervention group
Group type: COMPARATOR
Intervention: Routine implantation without bone graft surgery
Number of subjects: 16
Study 16536663 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 103
Study 16536663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 12749519 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg QD
Number of subjects: 5126
Study 12749519 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 200 mg QD
Number of subjects: 5126
Study 11023136 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-managed smoking cessation intervention (40‐min nurse visit with counseling, education, and contracting)
Number of subjects: 280
Study 11023136 — intervention group
Group type: COMPARATOR
Intervention: Usual care for diabetic smokers
Number of subjects: 280
Study 11023136 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-managed smoking cessation intervention
Number of subjects: 280
Study 9069573 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 879
Study 9069573 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 879
Study 8421118 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine toothpaste used 2x a day as a slurry rinse
Number of subjects: 14
Study 8421118 — intervention group
Group type: COMPARATOR
Intervention: Placebo toothpaste
Number of subjects: 14
Study 31730601 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 1 clinical trial participation
Number of subjects: 30
Study 28891445 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal diagnosis of dementia
Number of subjects: 319
Study 28891445 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-dementia drug treatment
Number of subjects: 319
Study 28891445 — intervention group
Group type: COMPARATOR
Intervention: Depression (Geriatric Depression Scale; GDS)
Number of subjects: 319
Study 28891445 — intervention group
Group type: COMPARATOR
Intervention: Quality of life in Alzheimer's disease (Qol-AD)
Number of subjects: 319
Study 28891445 — intervention group
Group type: COMPARATOR
Intervention: Knowledge about dementia
Number of subjects: 319
Study 26758039 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse methylprednisolone followed by a 25-month course of oral prednisolone (P group, n = 20)
Number of subjects: 40
Study 26758039 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined with mizoribine (150 mg/day for 24 months, M + P group, n = 20)
Number of subjects: 40
Study 26758039 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 40
Study 25189430 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.2 mg oral tablet one hour before surgery, plus 0.2 mg·day(‐1) transdermal patch placed one hour before surgery and removed four days after surgery or hospital discharge)
Number of subjects: 168
Study 25189430 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo)
Number of subjects: 168
Study 25189430 — intervention group
Group type: COMPARATOR
Intervention: Clonidine and Placebo (combined outcomes)
Number of subjects: 168
Study 22329667 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-coated components
Number of subjects: 68
Study 22329667 — intervention group
Group type: COMPARATOR
Intervention: Uncoated components
Number of subjects: 68
Study 22329667 — intervention group
Group type: COMPARATOR
Intervention: Cemented components
Number of subjects: 68
Study 21129211 — intervention group
Group type: EXPERIMENTAL
Intervention: PALM PLUS intervention (integrated guideline and training)
Number of subjects: 30
Study 21129211 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 30
Study 21129211 — intervention group
Group type: EXPERIMENTAL
Intervention: PALM PLUS intervention
Number of subjects: 30
Study 17679361 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin, 5 mg daily for 6 weeks
Number of subjects: 60
Study 17679361 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 60
Study 17679361 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Epigastric Pain Syndrome (before treatment)
Number of subjects: 60
Study 17679361 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Postprandial Disorders Syndrome (before treatment)
Number of subjects: 60
Study 16120036 — intervention group
Group type: EXPERIMENTAL
Intervention: NovoPen 3
Number of subjects: 48
Study 16120036 — intervention group
Group type: EXPERIMENTAL
Intervention: FlexPen
Number of subjects: 48
Study 16120036 — intervention group
Group type: EXPERIMENTAL
Intervention: NovoPen 3 and FlexPen
Number of subjects: 48
Study 12377205 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservation of the great auricular nerve (group A)
Number of subjects: 24
Study 12377205 — intervention group
Group type: COMPARATOR
Intervention: Sacrificing the great auricular nerve (group B)
Number of subjects: 24
Study 10541775 — intervention group
Group type: EXPERIMENTAL
Intervention: Repro-Dose morphine (RDM) once daily
Number of subjects: 47
Study 10541775 — intervention group
Group type: COMPARATOR
Intervention: MST Continuous (MST) twice daily
Number of subjects: 47
Study 7776913 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamphlet with brief advice
Number of subjects: 131
Study 7776913 — intervention group
Group type: EXPERIMENTAL
Intervention: Group dietary counselling
Number of subjects: 131
Study 7776913 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual counselling
Number of subjects: 131
Study 7776913 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietitian-based counselling
Number of subjects: 131
Study 2187009 — intervention group
Group type: EXPERIMENTAL
Intervention: fenfluramine treatment
Number of subjects: 7
Study 2187009 — intervention group
Group type: COMPARATOR
Intervention: placebo treatment
Number of subjects: 7
Study 89278 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged breast-feeding (more than 6 months)
Number of subjects: 236
Study 89278 — intervention group
Group type: COMPARATOR
Intervention: Breast-feeding for 2–6 months
Number of subjects: 236
Study 89278 — intervention group
Group type: COMPARATOR
Intervention: Weaning to cow's-milk-based formulas at less than 2 months
Number of subjects: 236
Study 30468936 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomodulating enteral nutrition (IMPACT group; IG)
Number of subjects: 40
Study 30468936 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral nutrition (Ensure group; EG)
Number of subjects: 40
Study 29730280 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicriteria optimization database (MCOD)
Number of subjects: 124
Study 29730280 — intervention group
Group type: COMPARATOR
Intervention: Clinical plan database (CPD)
Number of subjects: 124
Study 29730280 — intervention group
Group type: EXPERIMENTAL
Intervention: Replans using KBP predictions
Number of subjects: 124
Study 29730280 — intervention group
Group type: EXPERIMENTAL
Intervention: KBP predictions
Number of subjects: 124
Study 27066188 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus casei (4 × 10(8) CFU) with prebiotic Inulin (400 mg)
Number of subjects: 32
Study 27066188 — intervention group
Group type: COMPARATOR
Intervention: Control group (no synbiotic supplementation)
Number of subjects: 32
Study 24553574 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose ethanol
Number of subjects: 105
Study 24553574 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose ethanol
Number of subjects: 105
Study 24553574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 22682276 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider malaria training intervention
Number of subjects: 0
Study 22682276 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider malaria training intervention plus school-based intervention
Number of subjects: 0
Study 22682276 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined provider plus school-based intervention
Number of subjects: 0
Study 22682276 — intervention group
Group type: COMPARATOR
Intervention: Expected standard practice in malaria diagnosis and treatment
Number of subjects: 0
Study 22682276 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider intervention alone
Number of subjects: 0
Study 21060104 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (starting at 2000 mg/d)
Number of subjects: 156
Study 21060104 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (starting at 2 mg/kg/d)
Number of subjects: 156
Study 21060104 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Number of subjects: 156
Study 17996511 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan 100 mg
Number of subjects: 24
Study 15743365 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexloxiglumide 200 mg t.i.d. for 7 days
Number of subjects: 36
Study 15743365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 12038783 — intervention group
Group type: EXPERIMENTAL
Intervention: Single doses of tinzaparin (175 IU/kg)
Number of subjects: 37
Study 12038783 — intervention group
Group type: EXPERIMENTAL
Intervention: Single doses of tinzaparin (75 IU/kg)
Number of subjects: 37
Study 12038783 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinzaparin (weight-adjusted dosing)
Number of subjects: 37
Study 12038783 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinzaparin
Number of subjects: 37
Study 9696214 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF
Number of subjects: 815
Study 9696214 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovulation Induction
Number of subjects: 815
Study 8570785 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye movements only
Number of subjects: 0
Study 8570785 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous eye and rapid arm movements toward the target
Number of subjects: 0
Study 8570785 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous eye and arm movements with a restraint blocking the arm
Number of subjects: 0
Study 2763876 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary calcium intake (1752 mg elemental Ca per day)
Number of subjects: 10
Study 2763876 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dietary calcium intake (391 mg elemental Ca per day)
Number of subjects: 10
Study 2763876 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium infusion (2 mg Ca per kg body weight over 5 minutes)
Number of subjects: 10
Study 2763876 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcium load (500 mg as CaCO3)
Number of subjects: 10
Study 2763876 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplements (1500 mg Ca per day as CaCO3)
Number of subjects: 10
Study 2763876 — intervention group
Group type: COMPARATOR
Intervention: Low-Ca diet (approximately 400 mg Ca per day)
Number of subjects: 10
Study 7174 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbuterol 200 mug 4 times per day for 6 months
Number of subjects: 46
Study 7174 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol 150 mug 4 times per day for 6 months
Number of subjects: 46
Study 7174 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose aerosolized carbuterol
Number of subjects: 46
Study 7174 — intervention group
Group type: COMPARATOR
Intervention: High dose aerosolized isoproterenol
Number of subjects: 46
Study 30323359 — intervention group
Group type: EXPERIMENTAL
Intervention: 8IU intranasal oxytocin
Number of subjects: 16
Study 30323359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30323359 — intervention group
Group type: EXPERIMENTAL
Intervention: 24IU intranasal oxytocin
Number of subjects: 16
Study 30323359 — intervention group
Group type: EXPERIMENTAL
Intervention: IV oxytocin
Number of subjects: 16
Study 28619111 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-minute disconnection technique with a double-lumen tube (DLT)
Number of subjects: 50
Study 28619111 — intervention group
Group type: COMPARATOR
Intervention: Conventional one-lung ventilation (OLV) method
Number of subjects: 50
Study 27165949 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of aspirin
Number of subjects: 14464
Study 27165949 — intervention group
Group type: COMPARATOR
Intervention: No aspirin
Number of subjects: 14464
Study 25156269 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg/d, every night for ≥6 months)
Number of subjects: 120
Study 25156269 — intervention group
Group type: COMPARATOR
Intervention: Control (no statins)
Number of subjects: 120
Study 21842996 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal priming of negative relationships
Number of subjects: 0
Study 21842996 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal priming of ambivalent ties (high in positivity and negativity)
Number of subjects: 0
Study 21842996 — intervention group
Group type: COMPARATOR
Intervention: Subliminal priming of indifferent relationships
Number of subjects: 0
Study 21842996 — intervention group
Group type: COMPARATOR
Intervention: Subliminal priming of supportive relationships
Number of subjects: 0
Study 19641356 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous posterior tibial nerve stimulation (PTNS)
Number of subjects: 89
Study 19641356 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 89
Study 17438343 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral family intervention (BFI) - more intensive
Number of subjects: 0
Study 17438343 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral family intervention (BFI) - observed mothers
Number of subjects: 0
Study 17438343 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral family intervention (BFI) - observed mothers in more intensive intervention
Number of subjects: 0
Study 17438343 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 0
Study 16618008 — intervention group
Group type: EXPERIMENTAL
Intervention: Hallucination-focused integrative treatment (HIT)
Number of subjects: 63
Study 16618008 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (RT)
Number of subjects: 63
Study 12202967 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (Inderal, 40 mg)
Number of subjects: 60
Study 12202967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12202967 — intervention group
Group type: EXPERIMENTAL
Intervention: Arousal version of the slide show
Number of subjects: 60
Study 12202967 — intervention group
Group type: COMPARATOR
Intervention: Neutral version of the slide show
Number of subjects: 60
Study 10702882 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral doses of cilostazol (50 to 200 mg)
Number of subjects: 46
Study 10702882 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated oral administration of cilostazol (100 mg every 12 hours)
Number of subjects: 46
Study 10702882 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral doses of cilostazol (50 to 200 mg) and repeated doses (100 mg every 12 hours)
Number of subjects: 46
Study 8566601 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligation plus sclerotherapy (1 mL 1.5% tetradecyl injected just above each band)
Number of subjects: 41
Study 8566601 — intervention group
Group type: COMPARATOR
Intervention: Ligation alone
Number of subjects: 41
Study 8566601 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligation plus sclerotherapy
Number of subjects: 41
Study 1909152 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent transdermal glyceryl trinitrate (mean dose 18.2 mg over approximately 16 hours)
Number of subjects: 52
Study 1909152 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous treatment with 10 mg per 24 hours of transdermal glyceryl trinitrate
Number of subjects: 52
Study 1909152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 6688154 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile group (computerized drug profiles)
Number of subjects: 6186
Study 6688154 — intervention group
Group type: COMPARATOR
Intervention: No-profile group (control)
Number of subjects: 6186
Study 31910101 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 70 μg (2800 IU)/day
Number of subjects: 0
Study 31910101 — intervention group
Group type: COMPARATOR
Intervention: Anti-thyroid medication (ATD)
Number of subjects: 0
Study 31132509 — intervention group
Group type: COMPARATOR
Intervention: 10 Hz‐rTMS
Number of subjects: 16
Study 31132509 — intervention group
Group type: COMPARATOR
Intervention: pcTBS
Number of subjects: 16
Study 28368269 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group (n=52) received a multicomponent probiotic formulation of Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium longum and Saccharomyces boulardii once a day at a dose of 1.25×10^9 CFU from the time of initiation of enteral feeds till discharge
Number of subjects: 104
Study 28368269 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=52) received only breast milk
Number of subjects: 104
Study 28368269 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group
Number of subjects: 104
Study 25957978 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal tube
Number of subjects: 43
Study 25957978 — intervention group
Group type: COMPARATOR
Intervention: Face mask
Number of subjects: 43
Study 23713294 — intervention group
Group type: EXPERIMENTAL
Intervention: Wuhuang Tangkangling (decoction daily for 8 weeks)
Number of subjects: 100
Study 23713294 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone (15 mg x d(‐1) orally once a day) combined with insulin subcutaneous injection
Number of subjects: 100
Study 21606263 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose MDCT and CT enterography with adaptive statistical iterative reconstruction (ASIR)
Number of subjects: 48
Study 21606263 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose MDCT and CT enterography with ASIR
Number of subjects: 48
Study 21606263 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose 64-MDCT and CT enterography with filtered back projection (FBP)
Number of subjects: 48
Study 19665833 — intervention group
Group type: EXPERIMENTAL
Intervention: Load-distributing band CPR (LDB-CPR)
Number of subjects: 4
Study 19665833 — intervention group
Group type: COMPARATOR
Intervention: Manual CPR
Number of subjects: 4
Study 17353340 — intervention group
Group type: EXPERIMENTAL
Intervention: non-Carr-Purcell-Meiboom-Gill (non-CPMG) single-shot fast spin-echo (SS-FSE) sequence
Number of subjects: 24
Study 17353340 — intervention group
Group type: COMPARATOR
Intervention: EPI-based sequence
Number of subjects: 24
Study 15042546 — intervention group
Group type: EXPERIMENTAL
Intervention: Low AGE diet (L-AGE)
Number of subjects: 189